Table 2

Best-corrected visual acuity (ETDRS) after intravitreal injection in the IVB and IVB/IVF groups

Time point	Total	Group		Difference	95%CI		P values
Time point	Total	IVB	IVB/IVF	Difference	Lower	Upper	P values
Baseline
Mean±SD	52±19	57±16	48±17	9	−1	19	0.086*
Month 3
Mean±SD	62±11	63±11	60±10	−7	−12	−2	0.003†
Change (baseline—3)
Mean±SD	9±7	7±6	12±6	−5	−9	−1	0.008*
≥15 ETDRS letters	13(31.0%)	4(20.0%)	9(40.9%)	−20.9	−49.7	7.9	0.150‡
P-Within§		<0.001	<0.001
Month 6
Mean±SD	60±13	58±13	62±12	−13	−24	−1	0.029†
Change (baseline—6)
Mean±SD	7±11	1±10	13±9	−12	−18	−6	<0.001*
≥15 ETDRS letters	14(33.3%)	2(10.0%)	12(54.5%)	−44.5	−70.7	−18.4	0.006‡
P-within§		>0.99	<0.001

*Based on t-test.
†Adjusted for the baseline, based on analysis of covariance.
‡Based on logistic regression.
§Based on linear mixed model, multiple comparison considered by Bonferroni method.
IVB, intravitreal injection of bevacizumab; IVB/IVF, intravitreal injection of both bevacizumab and fasudil.